Decide at what price you'd be comfortable buying and we'll help you stay ready.
Corcept's product-led revenue base has expanded across the multi-year record, while operating earnings fluctuate as commercial and research spending changes. Modest property and equipment spending lets operating cash generation flow through as free cash flow, although stock compensation and working-capital movements make cash conversion less smooth.
Recent results extend product-sales growth and show a sharp operating recovery, while Lifyorli adds a new commercial revenue stream. The change matters to the earnings profile, but one quarter does not establish a lasting margin trajectory as commercialization costs continue to rise.
Whether Lifyorli sales continue to grow while operating margin holds up as commercialization spending increases.
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 81.3m | 159.2m | 251.2m | 306.5m | 353.9m | 366m | 401.9m | 482.4m | 675m | 761.4m | |
| (2.1m) | (3.6m) | (5.2m) | (5.5m) | (5.6m) | (5.3m) | (5.4m) | (6.5m) | (10.9m) | (13m) | |
| 79.3m | 155.6m | 246m | 301m | 348.3m | 360.7m | 396.5m | 475.9m | 664.2m | 748.4m | |
| (69m) | (102.7m) | (156.6m) | (189.4m) | (220.1m) | (236.2m) | (283.8m) | (368.6m) | (527.2m) | (703.6m) | |
| (45.2m) | (62.4m) | (81.3m) | (100.4m) | (105.3m) | (122.4m) | (152.8m) | (184.3m) | (280.3m) | (448.7m) | |
| (23.8m) | (40.4m) | (75.2m) | (89m) | (114.8m) | (113.9m) | (131m) | (184.4m) | (246.9m) | (254.9m) | |
| 10.2m | 52.9m | 89.5m | 111.6m | 128.2m | 124.5m | 112.6m | 107.3m | 137m | 44.8m | |
| (1.9m) | (500k) | 2.7m | 5.1m | 3.4m | 500k | 3.6m | 17.3m | 24.5m | 21.7m | |
| 1.9m | 456k | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | 0 | 0 | 0 | — | |
| (100k) | 400k | — | — | — | — | — | — | — | — | |
| 8.1m | 52.8m | 92.2m | 116.7m | 131.6m | 125m | 116.2m | 124.6m | 161.5m | 66.5m | |
| — | 109.5m | (16.7m) | (22.5m) | (25.6m) | (12.5m) | (14.8m) | (18.4m) | (20.3m) | 33.2m | |
| 8.1m | 162.4m | 75.4m | 94.2m | 106m | 112.5m | 101.4m | 106.1m | 141.2m | 99.7m | |
| 8.1m | 129.1m | 75.4m | 94.2m | 106m | 112.5m | 101.4m | 106.1m | 141.2m | 99.7m | |
| 0.07 | 1.03 | 0.60 | 0.77 | 0.85 | 0.89 | 0.87 | 0.95 | 1.24 | 0.83 |
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more